Stull DE, McBride D, Houghton K, Finlay AY, Balp MM. Correlation between UAS7 categorical health states and DLQI score bands to assess burden of disease and response to treatment in chronic idiopathic/spontaneous patients (CIU/CSU). Poster presented at the 23rd World Congress of Dermatology; June 2015. Vancouver, Canada.
Stull DE, McBride D, Houghton K, Balp MM. Are changes in chronic urticaria symptoms and sleep experience correlated?: a post-hoc analysis from phase II trials of omalizumab in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU). Poster presented at the 23rd World Congress of Dermatology; June 2015. Vancouver, Canada.
Stull DE, McBride DW, Houghton KF, Balp MM. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): a post-hoc analysis from 2 randomized, double-blind, placebo-controlled phase 3 trials of omalizumab. Poster presented at the American Academy of Dermatology 73rd Annual Meeting; March 21, 2015. San Francisco, CA. [abstract] J Am Acad Dermatol. 72(5):AB43. doi: 10.1016/j.jaad.2015.02.183
Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp MM. Correlations between changes in urticaria activity score, dermatologic-related quality of life, and urticaria-specific quality of life: results from the Ph III trials of omalizumab in CIU/CSU patients. Poster presented at the American Academy of Dermatology 72nd Annual Meeting; March 21, 2015. Denver, CO.
Stull DE, McBride D, Houghton K, Balp MM. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CU-Q2oL): is it informative about the response to treatment in CSU/CIU patients? Poster presented at the Maui Derm for Dermatologists; January 26, 2015. Maui, HI. Previously presented at the Fall Clinical Dermatology Conference.
Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled Phase III trials of omalizumab. Poster presented at the Maui Derm for Dermatologists; January 26, 2015. Maui, HI. Previously presented at the Fall Clinical Dermatology Conference.
Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled Phase III trials of omalizumab. Poster presented at the Winter Clinical Dermatology Conference; January 16, 2015. Kaanapali, HI. Previously presented at the Fall Clinical Dermatology Conference.
Stull D, McBride D, Houghton K, Balp M-M. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CUQ2oL): is it informative about the response to treatment in csu/ciu patients? Poster presented at the 2015 Winter Clinical Dermatology Conference; January 2015. Kaanapali, HI. Previously presented at the Fall Clinical Dermatology Conference.